| scholarly article | Q13442814 |
| P50 | author | David Capper | Q63366395 |
| Arianeb Mehrabi | Q67168816 | ||
| Andreas von Deimling | Q40381084 | ||
| Wilko Weichert | Q40935156 | ||
| P2093 | author name string | Albrecht Stenzinger | |
| Frederick Klauschen | |||
| Arne Warth | |||
| Peter Schirmacher | |||
| Marcus Renner | |||
| Benjamin Goeppert | |||
| Monika Nadja Vogel | |||
| Stephanie Roessler | |||
| Mohammadreza Hafezi | |||
| Lena Frauenschuh | |||
| Katja Boehmer | |||
| P2860 | cites work | BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer | Q62663734 |
| Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia | Q83983228 | ||
| Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1 | Q84789932 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Targeting the BRAF V600E mutation in multiple myeloma | Q27852220 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases | Q28250795 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 | ||
| Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions | Q34501265 | ||
| Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations | Q34547540 | ||
| Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions | Q34580542 | ||
| Clinical diagnosis and staging of cholangiocarcinoma | Q34631337 | ||
| BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome | Q34782265 | ||
| Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping | Q35705307 | ||
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes | Q36759538 | ||
| BRAF(E600) in benign and malignant human tumours | Q36921234 | ||
| Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer | Q37216703 | ||
| Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation | Q37667684 | ||
| Genetics of biliary tract cancers and emerging targeted therapies | Q37765099 | ||
| Targeting BRAF for patients with melanoma. | Q37817713 | ||
| The V599E BRAF mutation is uncommon in biliary tract cancers | Q38447459 | ||
| Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma | Q39788891 | ||
| Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma | Q43005729 | ||
| Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. | Q43815115 | ||
| Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. | Q43853831 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells | Q45392719 | ||
| Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. | Q46002239 | ||
| Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. | Q47280618 | ||
| Brainstem ganglioglioma successfully treated with vemurafenib | Q48189758 | ||
| Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. | Q54291167 | ||
| A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? | Q54441873 | ||
| Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. | Q54480523 | ||
| BRAF inhibition in refractory hairy-cell leukemia. | Q54509211 | ||
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 | ||
| P433 | issue | 7 | |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| immunohistochemistry | Q899285 | ||
| ??? | Q18556397 | ||
| P304 | page(s) | 1028-1034 | |
| P577 | publication date | 2013-12-06 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma | |
| P478 | volume | 27 |
| Q64079084 | Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway |
| Q51508576 | BRAF V600E mutation in biliary proliferations associated with α1 -antitrypsin deficiency. |
| Q35565384 | BRAF V600E mutational status in bile duct adenomas and hamartomas |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q50075039 | Biliary tract cancers : Molecular characterization and identification of novel prognostic markers |
| Q46087686 | Cholangiocarcinoma - evolving concepts and therapeutic strategies |
| Q58704645 | Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors |
| Q40914280 | Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma |
| Q60661741 | Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan |
| Q39453572 | Current biologics for treatment of biliary tract cancers |
| Q101353777 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer |
| Q101353785 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply |
| Q41553206 | Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. |
| Q38642455 | Emerging molecular targets and therapy for cholangiocarcinoma |
| Q39022105 | Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma |
| Q98159763 | Genetic analysis in the clinical management of biliary tract cancer |
| Q50127508 | Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers |
| Q91728336 | HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis |
| Q37525324 | Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review |
| Q53233317 | Monocentric study of bile aspiration associated with biliary brushing performed during endoscopic retrograde cholangiopancreatography in 239 patients with symptomatic biliary stricture. |
| Q34764681 | Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications |
| Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
| Q90308323 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma |
| Q92912017 | Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal |
| Q40564690 | Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer |
| Q41370055 | Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. |
| Q27853199 | Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations |
Search more.